ABSTRACT: Preclinical evidence in support of the potential utility of mGlu 5 NAMs for the treatment of a variety of psychiatric and neurodegenerative disorders is extensive, and multiple such molecules have entered clinical trials. Despite some promising results from clinical studies, no small molecule mGlu 5 NAM has yet to reach market. Here we present the discovery and evaluation of N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (27, VU0424238), a compound selected for clinical evaluation. Compound 27 is more than 900-fold selective for mGlu 5 versus the other mGlu receptors, and binding studies established a K i value of 4.4 nM at a known allosteric binding site. Compound 27 had a clearance of 19.3 and 15.5 mL/min/kg in rats and cynomolgus monkeys, respectively. Imaging studies using a known mGlu 5 PET ligand demonstrated 50% receptor occupancy at an oral dose of 0.8 mg/kg in rats and an intravenous dose of 0.06 mg/kg in baboons.
■ INTRODUCTION
The metabotropic glutamate (mGlu) receptors are an eightmembered family of class C G protein-coupled receptors (GPCRs) that are activated by L-glutamic acid, the major excitatory neurotransmitter of the mammalian central nervous system (CNS). Further stratification of the mGlu receptors is made based on a variety of considerations, including structure, downstream signaling partners, and pharmacology. Whereas group I mGlu receptors (mGlu 1 and mGlu 5 ) are found in postsynaptic locations and couple via G q to the activation of phospholipase C (PLC), both group II (mGlu 2−3 ) and group III (mGlu 4 and mGlu 6−8 ) receptors are found mainly in presynaptic locations and couple via G i /G o to the inhibition of adenylyl cylase activity. Common to all mGlu receptors are a seven transmembrane (7TM) α-helical domain that connects to a large bilobed extracellular amino-terminal domain, sometimes termed the "venus fly trap (VFT)" domain. Located within this VFT domain is the binding site for the native ligand; however, allosteric binding sites for small molecules have thus far been confined to the transmembrane domain. The structural and functional properties of the mGlu receptors have been reviewed extensively. 1, 2 In the search for compounds that are sufficiently selective for individual mGlu receptor subtypes, we have found allosteric modulation to be a successful approach. In fact, in many cases, such a strategy can be employed for the design of both positive allosteric modulators (PAMs) and negative allosteric modu-lators (NAMs) of the same receptor. 3 Among the most actively investigated and advanced areas within this field is that of mGlu 5 NAMs. 4, 5 Potential therapeutic applications for small molecule mGlu 5 NAMs are extensive and include addiction, 6 Alzheimer's disease (AD), 7 anxiety, 8 autism spectrum disorder (ASD), 9 fragile X syndrome (FXS), 10 the levodopa-induced dyskinesia (LID) experienced by many patients with Parkinson's disease (PD), 11, 12 major depressive disorder (MDD), 13 and obsessive-compulsive disorder (OCD). 14 Much of the preclinical work that has served to establish mGlu 5 antagonism as an exciting new mechanism for targeting these various conditions has been conducted with two related tool compounds, methyl-6-(phenylethynyl)-pyridine (1, MPEP) 15 and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (2, MTEP) 16 ( Figure 1 ). Both compounds are structurally similar disubstituted alkynes, a motif that has been exploited for the design of several other highly optimized mGlu 5 NAM compounds. 4, 5 While results from clinical studies have been reported with nonalkyne based mGlu 5 NAMs such as 3 (fenobam), 17, 18 4 (AZD9272), 19, 20 and 5 (AZD2066), 19 ,20 the most highly studied and advanced clinical compounds are three alkyne mGlu 5 NAMs: 6 (mavoglurant), 14 ,21−25 7 (basimglurant), 26−29 and 8 (dipraglurant) 30, 31 ( Figure 1 ). Still, failures to reach primary clinical end points with 6 14,22,23 and 7 28 point to the continued need for highly optimized mGlu 5 NAMs. It should be noted that a recent report from Pfizer has described cutaneous toxicities in cynomolgus monkey toxicology studies with three structurally related nonalkyne based mGlu 5 NAMs. 32 Given that other mGlu 5 NAMs that are not structurally related to the Pfizer compounds have been used in long-term, repeat dose studies in nonhuman primates (NHPs) 33, 34 and humans 14, [22] [23] [24] 28 without notes of a similar significant toxicity, it seems reasonable that such effects are not endemic to the mechanism. Still, these results make a compelling argument for using cynomolgus monkeys as the nonrodent species for toxicology studies in the event that our conclusion is incorrect.
Alkynes are potentially reactive functional groups. Pfizer has reported an instance of biliary epithelial hyperplasia in a NHP toxicology study with an alkyne-based mGlu 5 NAM developed by Wyeth. 35 This toxicity was believed to be linked to the reactivity of the alkyne based on metabolic studies that revealed extensive glutathione conjugation. 35 While this type of biotransformation does not always manifest in humans with alkyne-containing compounds, 25, 27 many research groups have sought to design novel mGlu 5 NAMs that are outside of this chemotype. 4, 5 We have actively pursued a variety of approaches toward that end over the past decade. 36, 37 For example, we conducted a high-throughput screen (HTS) of a collection of 160,000 compounds that identified multiple distinct mGlu 5 NAM hits. This same platform functions as our primary assay for lead optimization by measuring the ability of novel compounds to block the mobilization of calcium induced by an EC 80 concentration of glutamate in HEK293A cells that express rat mGlu 5 .
■ RESULTS AND DISCUSSION
Initial Analogs. Recently, we described the discovery of an in vivo tool compound 9 (VU0409106) 37−40 that resulted from the optimization of one of these HTS hits (Table 1) . That report focused exclusively on compounds with a benzamide core; 37 however, we were also interested in exploring picolinamide analogs as well (10−13, Table 1 ). Moving from the 3-fluorophenyl benzamide core (9) to an unsubstituted picolinamide core (10) reduced potency by approximately 8-fold; however, substitution of the picolinamide core at the 6-position with a methyl group (11) improved potency. In addition, structure−activity relationships (SARs) established in the benzamide series 37 translated to the picolinamides in the form of enhanced potency with the 5-fluoropyridin-3-yl ether (12) . Once again, 6-methyl substitution of the picolinamide core (13) improved potency relative to the unsubstituted analog 12. Buoyed by the encouraging results from this limited set of analogs and in search of a compound that represented a step forward from 9 to a compound worthy of advancement to clinical development, we devised a plan to prepare additional 6- 
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Article alkyl-picolinamide analogs. Herein, we report the successful execution of that strategy.
Synthesis of Compounds. The synthetic routes to the picolinamide analogs largely mirror those described for the benzamide mGlu 5 NAMs. 37 Briefly, 4-nitropyridine-N-oxides 14 were refluxed in concentrated hydrochloric acid to afford 4-chloropyridine-N-oxides 16 (Scheme 1 ) generated the target analogs.
Initial SAR. Even though compound 9 is a useful tool for acute behavioral studies in mice and rats, 37, 39 it has several properties that prevent its further development. In particular, 9 has moderate to high clearance in rats (Cl p 43 mL/min/kg) and cynomolgus monkeys (Cl p 24 mL/min/kg). 40 In addition, 9 has poor bioavailability following oral administration in rats (F < 5%) and is an inhibitor of CYP1A2 (IC 50 < 100 nM). Evaluation of the picolinamide analogs of 9 indicated that the 4-methylthiazol-2-yl amide contributed substantially to the potent inhibition of CYP1A2 (e.g., 10 CYP1A2 IC 50 < 100 nM), and SAR for mGlu 5 activity within the benzamide series showed limited tolerance for even subtle modifications on the thiazol-2-yl moiety. 37 Fortunately, analogs with a pyridin-2-yl replacement for the thiazol-2-yl ring appeared more amenable to substitution, and initial work in the picolinamide series was carried out in that context while taking advantage of SAR knowledge gained from the benzamide work ( Table 2) .
As expected, the majority of these pyridin-2-yl analogs (21− 32) proved to be potent antagonists of mGlu 5 on par with their thiazol-2-yl analogs (11 and 13) . In a majority of instances, analogs with the 5-fluoropyridin-3-yl ether exhibited slightly superior mGlu 5 potency compared to the pyrimidin-5-yl ether analogs; however, the 6-ethylpyridin-2-yl analogs 23 and 24 and 5-chloropyridin-2-yl derivatives 29 and 30 were an exception to this trend. Assays that measured the degree of binding to rat and human plasma and a human liver microsomes (HLM) cocktail assay with probe substrates for four common P450s 41 were used to profile several selected compounds. SAR with regard to the heteroaryl ether group was clear, as the pyrimidin-5-yl ether (Series A) analogs were consistently less bound to plasma than their 5-fluoropyridin-3-yl ether (Series B) analogs. No activity at 30 μM test compound was noted with regard to inhibition of CYP2D6, and inhibition of CYP3A4 and CYP2C9 ranged considerably. As anticipated, the most consistently potent P450 inhibition was observed with CYP1A2; however, there was another clear SAR with respect to the heteroaryl ether group. In this case, the pyrimidin-5-yl ether (Series A) analogs were less potent CYP1A2 inhibitors than the 5-fluoropyridin-3-yl ether (Series B) analogs.
Moving our attention to other portions of the chemotype, we prepared further analogs that revealed additional SAR. Modifications made in the context of the 5-fluoropyridin-2-yl amide found in analogs 27 and 28 are depicted here ( Table 3) . Installation of a methyl group at the 2-position of the pyrimidin-5-yl ether (33) resulted in a 3-fold loss in potency relative to 27. While this modification increased the extent of binding to plasma, it also reduced inhibition versus CYP1A2 and CYP2C9. Moving to a larger cyclopropyl group at the 2-position of the pyrimidin-5-yl ether (34) substantially eroded potency at mGlu 5 , indicating minimal tolerance for steric bulk at this position. Likewise, replacement of the 6-methyl group on the picolinamide core with a difluoromethyl group (35) led to an approximately 5-fold loss in mGlu 5 potency, illustrating little tolerance for modification at that position. Replacement of the 5-fluoro group of the pyridin-3-yl of 28 with a 5-chloro group (36) resulted in only a slight drop in potency. Replacement of the meta-halogen atoms found in 28 and 36 with the paramethyl group in 6-methylpyridin-3-yl ether 37 reduced mGlu 5 potency by 50-and 20-fold, respectively.
In Vivo Pharmacokinetics (PK) Studies. Previous studies in our laboratories with pyrimidin-5-yl ethers identified this ring as a substrate for aldehyde oxidase (AO)-mediated metabolism. 38, 40 Thus, given the likelihood that several of our interesting new compounds would be subject to non-P450-mediated metabolism, we decided to move directly into an in vivo setting to evaluate the clearance of a variety of select analogs (Table 4) . In these studies, the three analogs with the 5-fluoropyridin-2-yl amide group (27, 28 , and 33) exhibited superior profiles compared to the other compounds that contained pyridin-2-yl amides with 6-alkyl (21−23) or 6-fluoro (26) groups. The plasma clearance of 26 was greater than hepatic blood flow, 42 which suggests that the instability previously observed in rat plasma for this compound (Table  2) is not merely an in vitro phenomenon. Blocking the 2-position of pyrimidin-5-yl ether (33) reduced clearance and lengthened mean residence time relative to unsubstituted analog 27. Such a result points toward this position as one potential site for metabolism, which is consistent with prior studies on related analog 9. 
Article were subsequently evaluated in tissue distribution studies (Table 5 ) using oral dosing. Acceptable CNS penetration was achieved with all three compounds, and unbound brain to unbound plasma ratios (K p,uu ) were near unity with 27 and 28, indicating distribution equilibrium between the compartments and a low probability of these two compounds being substrates for transporters in rats. 43 The K p,uu observed for 33 raises the possibility of active transport with this compound; however, additional studies would be required to conclusively determine if that was indeed the case. All compounds achieved unbound brain levels in excess of their respective mGlu 5 functional potency at the dose used in these experiments (10 mg/kg).
Compounds 27 and 28 were particularly attractive from this b Amplitude of response in the presence of 30 μM test compound as a percentage of maximal response (100 μM glutamate); an average of n ≥ 3 independent experiments. c f u = fraction unbound; equilibrium dialysis assay.
d Assayed in pooled HLM in the presence of NADPH with CYP-specific probe substrates perspective, reaching unbound brain levels of 18-and 10-fold over their functional potency, respectively. Considering their favorable profiles, compounds 27 and 28 were selected for oral pharmacokinetic and bioavailability studies in rats and cynomolgus monkeys (Table 6 ). Cynomolgus monkeys were chosen as a second preclinical species as it has been established that AO activity varies across species. Specifically, AO activity is highest in humans and NHPs, moderate in rats, and undetectable in dogs. 44 Using in vitro methods described previously for 9, 38,40 we confirmed that AO contributed significantly to the metabolism of 27 in rats, cynomolgus monkey, and human hepatic S9 fractions ( Figure  2 ). Oral exposure was significant as bioavailability exceeded 50% with both compounds in rats. Compound 27 exhibited an earlier and slightly higher plasma C max than 28; however, the lower clearance of 28 resulted in prolonged exposure and larger area under the curve (AUC) than observed for 27. The PK results from analogous studies in cynomolgus monkeys showed these compounds to be similar in that both compounds showed a clearance of approximately one-third of hepatic blood flow. 42 Bioavailability, while lower than that observed in rats, was still >30% in each case. With largely attractive in vivo PK profiles, both compounds were advanced into further studies to identify additional factors for differentiation.
Ancillary Pharmacology. To judge the selectivity of these analogs versus the other members of the mGlu receptor family, the effects of both 27 and 28 at 10 μM on the orthosteric agonist concentration response curve (CRC) were measured in fold-shift experiments. 45, 46 No significant effects on the agonist CRC were noted with either compound, indicating excellent selectivity for mGlu 5 . To assess potential ancillary pharmacology, both compounds were screened at 10 μM in a commercial radioligand binding assay panel of 68 diverse and clinically relevant targets (see Supporting Information). 47 While 27 had no significant responses at any target, where significant responses are defined as inhibition of more than 50% of radioligand binding, one significant response of 86% inhibition was noted for 28 at the dopamine transporter (DAT). For comparison, 27 only inhibited DAT at a level of 34%. A subsequent CRC was obtained, and 28 was found to inhibit radioligand binding with an IC 50 of 1.54 μM. Since inhibition of DAT is associated with abuse potential, 48 we next evaluated 28 in a functional cell-based assay that measured inhibition of dopamine uptake. 49 Indeed, consistent with results obtained from the binding assay, 28 exhibited an IC 50 of 1.38 μM in this assay. While 28 is more than 400-fold selective for mGlu 5 versus DAT, the lack of concern regarding this target in the case of 27 was viewed as a positive for that compound. With its preferable P450 inhibition profile (Table 2 ) and the higher unbound brain concentrations achieved in rats also in its favor, the decision was made to proceed with additional detailed characterization of 27.
Detailed Characterization of 27. Having narrowed our interest to analog 27, we carried out a more thorough characterization of its interaction with mGlu 5 ( Figure 3) . First, to ensure that there was no appreciable species difference in the mGlu 5 activity of 27, we carried out our calcium mobilization assay in HEK293A cells expressing the human receptor ( Figure 3A ). As anticipated, the potency difference between rat (IC 50 = 11 nM) and human mGlu 5 (IC 50 = 14 nM) was negligible. To study the effects of 27 on mGlu 5 activity in a native system, experiments in rat cortical astrocytes were conducted ( Figure 3B ). As expected, 27 induced a concentration-dependent rightward shift of the glutamate CRC and decreased the maximal response to glutamate. To investigate whether 27 interacted with the mGlu 5 allosteric site that is common to many mGlu 5 NAMs such as 1 and 2 (Figure 1 ), we also carried out a competition radioligand binding assay with [ 3 H]-3-methoxy-5-(pyridin-2-ylethynyl)pyridine (39) 50 ( Figure  3C ) in membranes prepared from HEK293A cells expressing rat mGlu 5 . This study confirmed the interaction of 27 with this known binding site (mGlu 5 K i = 4.4 nM). We also performed saturation binding experiments with increasing concentrations of [ 3 H]-38 in the presence and absence of multiple concentrations of 27 ( Figure 3D ,E). Increasing concentrations of 27 had no effect on the B max of the radioligand but increased the K d as shown ( Figure 3D ), a finding that suggests a competitive interaction between 27 and [ 3 H]-39. Scatchard analysis ( Figure 3E ) of the results plotting bound/free versus a Average n = 2, male Sprague−Dawley rats; dose = 10 mg/kg; vehicle = 10% polysorbate 80 in 0.5% methyl cellulose; t = 1 h post-dose. b Calcium mobilization mGlu 5 assay; values are an average of n ≥ 3 independent experiments. c f u = Fraction unbound; equilibrium dialysis assay; brain = mouse brain homogenates.
d K p = total brain to total plasma ratio. e K p,uu = unbound brain (brain f u × total brain) to unbound plasma (plasma f u × total plasma) ratio.
Article bound ligand demonstrated that addition of 27 induced a change in slope of the regression line (change in K d ) but had no effect on the x-intercept (no change in B max ). These data are consistent with 27 competitively displacing [ Each of these studies combine to conclusively establish that 27 binds in a competitive manner to the aforementioned known mGlu 5 allosteric binding site. With a detailed understanding of the pharmacology of 27 in hand, we moved the compound into a host of additional assays designed to identify potential risks for clinical development (Table 7) . Permeability and potential for P-glycoprotein (Pgp)-mediated efflux was assessed in both Madin−Darby canine kidney (MDCK) cells transfected with the human MDR1 gene 52 and human colon carcinoma derived Caco-2 cells. 53 Permeability was moderate, and efflux ratios were near unity in 
Article both cell lines, indicating a low potential for transportermediated efflux. A definitive and expanded assessment of the ability of 27 to reversibly inhibit the metabolism of isoformselective probe substrates of P450s was conducted. Results were generally consistent with the preliminary results ( Table 2) with moderate inhibition of CYP1A2 observed. In parallel to these studies, the potential for 27 to time-dependently inhibit each P450 was assessed with no evidence of time-dependent inhibition noted in any case. To shed further light on the likely human PK profile of 27, the stability of the compound was assessed in human cryopreserved hepatocytes, a system which is potentially useful for evaluating compounds with non-P450-mediated routes of metabolism such as AO. 54 Gratifyingly, the predicted hepatic clearance in humans using this method was low with a half-life of more than 5 h. To assess any potential cardiac liabilities, 27 was subjected to a commercial ion channel panel. 55 Fortunately, no significant risks were identified in this panel. Finally, the potential mutagenic activity of 27 was investigated in the bacterial reverse mutation assay (Ames assay), 56 and no mutagenic responses were noted in any of the five strains either in the presence or absence of S9 metabolic activation. Encouraged by the overall profile of 27, we advanced this compound to behavioral assays in the rat.
Behavioral Pharmacology. It is well-known that mice will bury foreign objects such as glass marbles in deep bedding. Likewise, pretreatment with low doses of benzodiazepines and multiple mGlu 5 NAM tool compounds have been shown to inhibit this behavior. 57 It has been argued recently that the marble burying assay models the repetitive and perseverative behavior associated with OCD as opposed to novelty-induced anxiety. 58 We have also employed this rapid assay that utilizes naïve mice as a frontline behavioral screen for our discovery programs directed toward mGlu 5 NAMs. 36, 37 Using intraperitoneal (IP) dosing as a convenient route for rapidly and accurately dosing large numbers of animals, we examined the effects of 27 in this test ( Figure 4A ). Dose-dependent effects on marble burying were observed, and all doses ≥0.3 mg/kg produced significant effects relative to the vehicle control. The 3.0 mg/kg dose produced an effect on marble burying on par with the positive control 2 (15 mg/kg) in this study. A satellite experiment was conducted using the 3.0 mg/kg dose, and brain samples were collected and analyzed for exposure of 27. At 15 min post-dose of 27, which correlates to the initiation time point of the marble burying study, the total brain concentration of 27 was 1.48 μM. Calculation of the unbound brain concentration using equilibrium dialysis data (Table 5 ) yields a level of 115 nM, which is approximately 10-fold more than the functional mGlu 5 activity.
Having observed efficacy in this model of anxiety/OCD, we next studied 27 in an animal model of depression as well. The forced swim test (FST) measures the duration of immobility observed in rats suspended in a tank of water from which they cannot escape. 59 Many clinical antidepressants are able to reduce the time that the animals are immobile while increasing the time that they are active. Furthermore, certain mGlu 5 NAMs have also shown efficacy in this model of depression. 60 Examination of 27 in this assay showed a dose-dependent ability of the compound to reduce the duration of immobility indicative of antidepressant activity ( Figure 4B ). This result compares favorably to the literature report for 7 in the same assay, where that compound had a minimum efficacious dose of 10 mg/kg (PO). 60 The high dose used in this study (30 mg/kg 
Article IP) produced an efficacy equivalent to that of the positive control, ketamine, a known antagonist of the N-methyl-Daspartate (NMDA) receptor. Though ketamine is an older drug and produces undesirable psychotomimetic side effects, more recent clinical studies have shown that it can induce a rapid antidepressant effect in patients with treatment-resistant depression (TRD). 61 A report from last year implicated the activation of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor by a specific ketamine metabolite rather than direct antagonism of the NMDA receptor by ketamine as the potential source of these rapid antidepressant effects. 62 Interestingly, prior studies have shown that the antidepressant activity in the FST with mGlu 5 NAM 2 involved signaling through the NMDA but not the AMPA receptor. 63 Thus, the mechanisms by which ketamine and mGlu 5 Figure 5A . Maximum occupancy of 80% was achieved at 10 mg/kg 27 ( Figure 5B ). Plasma samples were collected throughout the study. Plotting the maximum unbound plasma concentration of 27 versus RO resulted in an unbound level Occ 50 of 13 nM ( Figure 5C ). Plotting the dose of 27 versus the RO normalized to the maximum displacement of [
18 F]-41 gave an RO 50 of 0.8 mg/kg ( Figure 5D ).
Based on the RO results in rats, we next investigated whether similar results would be obtained in NHPs. As such, we advanced 27 into studies in baboons using the same radiotracer [
18 F]-41 ( Figure 6 ). The design for this experiment was very similar to the aforementioned study in rats; however, in this case, both 27 and the radiotracer were delivered via IV administration. There was a clear reduction in the uptake of [ 18 F]-41 relative to baseline that followed a dose-dependent relationship with 27 ( Figure 6A,D,E) . The maximum dose resulted in 89% RO of mGlu 5 . Plasma samples were again taken throughout the study to analyze 27 levels, and RO was plotted against the plasma maximum to arrive at a total plasma Occ 50 of 56 nM ( Figure 6B ). If one assumes that human and baboon plasma protein binding is similar, then this equates to a plasma unbound Occ 50 of 6.7 nM, which is within 2-fold of that observed in the rodent study. The effective IV dose that produces 50% RO (RO 50 ) was determined to be 0.06 mg/kg ( Figure 6C ). 
Article ■ CONCLUSION Continuation of our mGlu 5 NAM discovery program that began with a cell-based HTS has culminated in the identification of the highly optimized compound 27 (VU0424238). 65 Compound 27 is a highly potent and selective antagonist of mGlu 5 with a favorable preclinical profile. The molecule has low-moderate clearance and good oral bioavailability in two species. Compound 27 displays CNS penetration in rodents, and we believe that the compound is a low risk for transporter-mediated efflux and drug−drug interactions. While the compound is a moderate inhibitor of CYP1A2, this aspect is considered manageable. Importantly, the compound is active in preclinical models of anxiety/OCD and depression, both of 
Article which are assays where mGlu 5 NAMs have shown activity in the past. Moreover, a clinically useful radiotracer has been used to demonstrate mGlu 5 RO by 27 in both rodents and NHPs. Based on the totality of data, we have selected 27 for advancement to clinical development including studies designed to enable an investigational new drug (IND) application. Here is the public disclosure of the chemical structure of 27, our candidate for clinical studies. Future publications describing detailed metabolic profiling, chemical process development and formulation, and toxicology studies are under preparation and will be communicated in the near future.
■ EXPERIMENTAL SECTION
Synthetic Procedures and Characterization Data. General. All NMR spectra were recorded on a 400 MHz AMX Bruker NMR spectrometer. Purity. Low-resolution reverse phase LCMS analysis was used to assess compound purity at two wavelengths: 215 and 254 nm. All analogs were at least 95% pure according to this analysis. Lowresolution reverse phase LCMS analysis was performed using an Agilent 1200 system comprising a binary pump with degasser, highperformance autosampler, thermostated column compartment, diodearray detector (DAD), and a C18 column. Flow from the column was split to a 6130 SQ mass spectrometer and Polymer Laboratories ELSD. The MS detector was configured with an electrospray ionization source. Data acquisition was performed with Agilent Chemstation and Analytical Studio Reviewer software. Method 1: Samples were separated on a ThermoFisher Accucore C18 column (2.6 μm, 2.1 × 30 mm) at 1.5 mL/min, with column and solvent temperatures maintained at 45°C. The gradient conditions were 7− 95% acetonitrile in water (0.1% TFA) over 1.4 min. Low-resolution mass spectra were acquired by scanning from 135 to 700 atomic mass units (AMU) in 0.25 s with a step size of 0.1 AMU and peak width of 0.03 min. Drying gas flow was 11 L/min at a temperature of 350°C and a nebulizer pressure of 40 psi. The capillary needle voltage was 3000 V, and the fragmentor voltage was 100 V. Method 2: Samples were separated on a ThermoFisher Accucore C18 column (2.6 μm, 2.1 × 30 mm) at 1.5 mL/min, with column and solvent temperatures maintained at 45°C. The gradient conditions were 7−95% acetonitrile in water (0.1% TFA) over 1.1 min. Low-resolution mass spectra were acquired by scanning from 135 to 700 AMU in 0.25 s with a step size of 0.1 AMU and peak width of 0.03 min. Drying gas flow was 11 L/ min at a temperature of 350°C and a nebulizer pressure of 40 psi. The capillary needle voltage was 3000 V, and the fragmentor voltage was 100 V. Method 3: Samples were separated on a Restek Aqueous C18 column (3 μm, 3.2 × 30 mm) at 1.25 mL/min, with column and solvent temperatures maintained at 45°C. The gradient conditions were 10−100% acetonitrile in water (0.1% TFA) over 2 min. Lowresolution mass spectra were acquired by scanning from 100 to 1500 AMU in 0.25 s with a step size of 0.1 AMU and peak width of 0.03 min. Drying gas flow was 11 L/min at a temperature of 350°C and a nebulizer pressure of 40 psi. The capillary needle voltage was 3000 V, and the fragmentor voltage was 70 V.
Preparation of Compound 27. 4-Chloro-2-methylpyridine-Noxide (16a). 2-methyl-4-nitropyridine 1-oxide 14a (5.0 g, 32 mmol, 1.0 equiv) was dissolved in concentrated HCl (80 mL) and refluxed for 3 days. The reaction was cooled, and the excess concentrated HCl was removed in vacuo. The viscous oil was neutralized with 10% K 2 CO 3 and extracted with CH 2 Cl 2 (5×). The combined organics were dried (MgSO 4 ), filtered, and concentrated in vacuo. Purification by flash chromatography on silica gel afforded 3.49 g (75%) of the title compound as a yellow solid.
Alternative Procedure: 4-Chloro-2-methylpyridine 15a (5.0 g, 39 mmol, 1.0 equiv) and hydrogen peroxide-urea adduct (7.37 g, 78.4 mmol, 2.0 equiv) were dissolved in THF (196 mL) and cooled to 0°C
. Trifluoroacetic anhydride (12 mL, 86.3 mmol, 2.2 equiv) was added dropwise over 15 min, and the reaction was allowed to warm to room temperature. After determination of the completion of the reaction by LCMS (approximately 45 min), the reaction was cooled to 0°C and quenched with a 10% aqueous solution of sodium thiosulfate. 6-Methyl-4-(pyrimidin-5-yloxy)picolinonitrile (19a). Compound 17a (4.0 g, 26 mmol, 1.0 equiv), 5-hydroxypyrimidine 18a (5.56 g, 57.9 mmol, 2.2 equiv), K 2 CO 3 (7.24 mg, 52.4 mmol, 2.0 equiv), and DMF (66 mL) were added to a reaction vessel and heated at 80°C for 16 h. The reaction was filtered and concentrated on silica gel (25 g ). The silica gel was loaded on top of a fresh bed of silica gel and washed with 50% EtOAc/hexane. The solvents were removed in vacuo, and the crude solid was purified by flash chromatography on silica gel to afford 4.31 g (77%) of the title compound as a pale-yellow solid. 6-Methyl-4-(pyrimidin-5-yloxy)picolinic acid (20a). Compound 19a (4.31 g, 20.3 mmol, 1.0 equiv) was dissolved in dioxane (90 mL), and 2 N NaOH (45 mL) was added. The mixture was refluxed for 18 h, and after cooling, the reaction was neutralized with 2 N HCl (45 mL). The water and solvent were removed in vacuo, and the crude reaction was dissolved in 10% MeOH/CH 2 Cl 2 . The undissolved salt was filtered off, and the solvents were removed in vacuo to afford 4.65 g (99%) of the title compound as a white solid which was used without further purification.
N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)-picolinamide (27) . 
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Article dissolved in pyridine (485 mL) in a flame-dried round-bottom flask. The reaction was cooled to −15°C, and phosphorus oxychloride (7.47 mL, 80.14 mmol, 1.1 equiv) was added dropwise while keeping the temperature below −15°C. After stirring for 30 min at −15°C, the reaction was quenched with ice−water and neutralized with 10% K 2 CO 3 . The mixture was extracted with EtOAc (3×), and the combined organics were dried (MgSO 4 ■ ASSOCIATED CONTENT
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